Arm and Leg Sarcomas Follow Surprisingly Different Surgical Roads, 24-Year Study Finds

Synovial sarcoma is one of the rarest and most deceptive soft-tissue cancers known to medicine. It tends to strike young adults, often lurks silently for years before diagnosis, and is notorious for relapsing long after patients believe they are in the clear. For decades, surgeons and oncologists have treated it largely as a single disease, tailoring therapy to tumor size, grade and stage while paying relatively little attention to where in the body the tumor arises. Now a German research team has presented evidence that the anatomical location of an extremity synovial sarcoma—arm versus leg—may shape not only how the disease is surgically managed but also how likely patients are to suffer complications after the operation.

The study, conducted at BG University Hospital Bergmannsheil in Bochum and published in the Journal of Cancer Research and Clinical Oncology, followed 59 consecutive patients with histologically confirmed synovial sarcoma of the extremities treated over a 24-year period between 2000 and 2023. Of these, 23 tumors arose in the upper extremity and 36 in the lower extremity. The researchers set out with a deceptively simple question: does the limb in which the tumor sits influence the surgical pathway and the postoperative course, or is location merely a bystander variable with no practical consequence? Their findings suggest the answer is far from trivial.

The co-primary endpoints of the analysis were the presence of a microscopically positive margin, designated R1, at the initial resection, and any postoperative complication within eight weeks of surgery, graded according to the widely used Clavien–Dindo classification. Margin status is a cornerstone of sarcoma surgery because residual microscopic disease at the cut edge is associated with local recurrence and, in many series, with diminished survival. Achieving an R0 resection—complete removal with microscopically clear margins—is the explicit goal of every limb-sparing sarcoma operation.

What the team found was a striking asymmetry between the two anatomical groups. Positive margins at the index operation were recorded in 14 of 23 upper-extremity patients, or 61 percent, compared with only 5 of 36 lower-extremity patients, or 14 percent. Expressed as an odds ratio, upper-extremity tumors carried a nearly tenfold higher likelihood of an R1 margin at the first surgery, at 9.64 with a 95 percent confidence interval of 2.73 to 34.1 and a P value below 0.001. Neoadjuvant therapy, given before surgery to shrink the tumor, was also far more common in the upper-extremity group, at 39 percent versus 8 percent, a difference that reached statistical significance with P equal to 0.007.

The authors interpret this pattern as a reflection of surgical anatomy rather than of biology. The arm and hand are crowded, functionally dense territories. Vital nerves, vessels and tendons course through narrow compartments, and resecting a sarcoma with a wide cuff of healthy tissue—the standard for sarcoma surgery—often collides with the imperative to preserve hand and arm function. In the forearm and wrist, where critical structures lie millimeters beneath the skin, achieving a clear margin may be anatomically impossible without sacrificing essential function. The leg, by contrast, offers more expansive soft-tissue envelopes, particularly in the thigh, where wide resections can be accommodated with less functional penalty. This anatomical headroom appears to translate into cleaner first-pass margins.

Yet the trade-off ran in the opposite direction when the researchers examined complications. Any postoperative complication within eight weeks occurred in only 13 percent of upper-extremity patients but in 53 percent of lower-extremity patients, yielding an odds ratio of 0.13 for upper-extremity surgery relative to lower-extremity surgery, with a 95 percent confidence interval of 0.03 to 0.53 and P equal to 0.002. Major complications, the more severe grades of the Clavien–Dindo scale, followed the same trend, affecting 9 percent of upper-extremity patients and 39 percent of lower-extremity patients, with P equal to 0.015. Lower-extremity sarcoma surgery, typically involving larger resections, more extensive reconstruction, and the hemodynamic and wound-healing stresses of the leg, clearly extracts a heavier early toll.

Reconstructive strategy also diverged between the two groups. Tumors of the leg, particularly after wide resections, frequently demanded flap coverage, skin grafts and other reconstructive procedures to close large soft-tissue defects, whereas upper-extremity cases more often required staged or secondary procedures, including planned re-excision to secure clear margins after an initial R1 result. Importantly, the study found that definitive R0 resection was ultimately achieved in all patients. Even when the first operation in an upper-extremity case left microscopic disease behind, re-excision successfully converted the margin status. The message is one of cautious reassurance: the anatomical disadvantage of the arm is real, but it is surgically recoverable through vigilant follow-up and willingness to operate again.

The oncological outcomes add another layer of nuance. Seven of the nine distant metastases observed in the cohort occurred in patients with lower-extremity tumors, and several of these events emerged beyond six years after treatment, underscoring synovial sarcoma’s reputation as a late-relapsing disease. Ten-year metastasis-free survival was 90 percent in the upper-extremity group versus 56 percent in the lower-extremity group. Because the study was single-center, retrospective and modest in size, the authors deliberately classified these time-to-event findings as exploratory; the log-rank comparison yielded a P value of 0.095, which does not meet conventional thresholds of statistical significance. Still, the direction of the difference aligns with the larger tumor volumes and deeper compartments often seen in leg sarcomas, and the long tail of metastatic risk serves as a sobering reminder that synovial sarcoma follow-up must extend well beyond the five-year mark commonly used for many other cancers.

Methodologically, the study draws on a rigorous institutional registry. Screening of 1,060 registry entries from January 2000 to December 2023 identified the 59 surgically treated extremity synovial sarcomas after exclusion of entries that failed histological or anatomical eligibility criteria. Statistical analysis employed Fisher exact tests and the Mann–Whitney U test for group comparisons, and Kaplan–Meier curves with log-rank tests for survival endpoints. The researchers were careful to frame their conclusions within the limits of the design: this was a retrospective single-center cohort, and the exploratory survival findings require multicenter validation before they can inform practice guidelines. The study was conducted in line with the Declaration of Helsinki, with ethics approval from Ruhr University Bochum and written informed consent from all participants.

The clinical implications are nonetheless compelling. If upper-extremity synovial sarcomas systematically arrive at the operating table with a higher risk of positive margins, then surgical planning for these tumors should anticipate the need for neoadjuvant therapy and planned re-excision from the outset, rather than treating a positive margin as a surprise. Conversely, the high complication burden of lower-extremity surgery argues for intensified perioperative care, aggressive wound surveillance and perhaps earlier mobilization protocols in these patients. Above all, the study reframes anatomical location as an actionable variable in sarcoma care rather than a descriptive footnote. For a disease in which a single millimeter of residual tissue can set the stage for recurrence years later, understanding how the body’s own geography constrains the surgeon’s knife may prove as important as any drug in the oncological arsenal.

Subject of Research: Upper- versus lower-extremity synovial sarcoma: surgical margins, postoperative morbidity and long-term outcomes in a 24-year cohort

Article Title: Upper- versus lower-extremity synovial sarcoma: distinct surgical pathways and postoperative morbidity in a 24-year cohort

Article References: Weskamp, P., Drysch, M., Fiedler, A., Schmidt, S. V., Reinkemeier, F., Steubing, Y., Lehnhardt, M., Dadras, M., Puscz, F., & Wallner, C. (2026). Upper- versus lower-extremity synovial sarcoma: distinct surgical pathways and postoperative morbidity in a 24-year cohort. Journal of Cancer Research and Clinical Oncology, 152(9), Article 181. https://doi.org/10.1007/s00432-026-06619-1

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06619-1

Keywords: synovial sarcoma, soft-tissue sarcoma, surgical margins, R1 resection, re-excision, postoperative complications, Clavien–Dindo, neoadjuvant therapy, metastasis-free survival, reconstruction, surgical oncology, extremity tumors